Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Report for September

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 8,346,026 shares, an increase of 71.9% from the September 15th total of 4,853,831 shares. Approximately 5.9% of the shares of the company are sold short. Based on an average daily trading volume, of 2,551,015 shares, the days-to-cover ratio is presently 3.3 days.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new position in shares of Inventiva in the first quarter worth approximately $1,111,000. Persistent Asset Partners Ltd bought a new stake in shares of Inventiva during the 4th quarter valued at $603,000. Engineers Gate Manager LP lifted its stake in shares of Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares in the last quarter. Finally, Platt Investment Counsel LLC bought a new position in Inventiva in the 3rd quarter worth $45,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Stock Performance

NASDAQ:IVA traded down $0.17 during mid-day trading on Friday, hitting $2.94. 4,854,208 shares of the company traded hands, compared to its average volume of 2,895,422. The stock’s fifty day moving average price is $4.04 and its 200-day moving average price is $4.47. Inventiva has a one year low of $2.82 and a one year high of $7.98.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million during the quarter. Analysts forecast that Inventiva will post -0.81 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Truist Financial boosted their target price on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Wall Street Zen upgraded shares of Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Guggenheim lifted their price target on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Finally, Weiss Ratings downgraded shares of Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.86.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.